Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy

Yusuke Okuma, Makoto Saito, Yukio Hosomi, Toshikazu Sakuyama, Tatsuru Okamura, Yusuke Okuma, Makoto Saito, Yukio Hosomi, Toshikazu Sakuyama, Tatsuru Okamura

Abstract

Purpose: Thymic malignancies, comprising thymoma and thymic carcinoma, are rare. Consequently, optimal chemotherapy for advanced thymic malignancies remains controversial. Platinum-based chemotherapy is currently the consensus treatment based on the results of single-arm phase II trials and retrospective investigations. However, comparison of cisplatin-based and carboplatin-based chemotherapy has yet to be undertaken; the effectiveness of the addition of anthracycline also remains uncertain.

Methods: In the present study, clinical trials and retrospective data regarding platinum-based chemotherapy were analyzed. The endpoint was the response rate to each chemotherapy. For advanced thymoma, we compared platinum with anthracycline-based chemotherapy and platinum with non-anthracycline-based chemotherapy. For advanced thymic carcinoma, anthracycline-based versus non-anthracycline-based chemotherapy and carboplatin-based versus cisplatin-based chemotherapy were compared. This analysis included a retrospective study of response of advanced thymic carcinoma to irinotecan and cisplatin in our institution.

Results: The response rate for the 314 patients from 15 studies with advanced thymoma, including both prospective and retrospective data, was 69.4% [95% confidence interval (CI) 63.1-75.0%] for platinum with anthracycline-based chemotherapy and 37.8% (95% CI 28.1-48.6%; p < 0.0001) for platinum with non-anthracycline-based chemotherapy. The response rates after anthracycline-based and non-anthracycline-based chemotherapy for advanced thymic carcinoma were similar (41.8 vs. 40.9%; p < 0.91), whereas the response rates after cisplatin-based and carboplatin-based chemotherapy for advanced thymic carcinoma differed significantly (53.6 vs. 32.8%; p = 0.0029) in 206 patients from 10 studies.

Conclusions: Platinum with anthracycline-based chemotherapy is an optimal combination for advanced thymoma. For advanced thymic carcinoma, cisplatin-based chemotherapy may be superior to carboplatin-based chemotherapy.

Figures

Fig. 1
Fig. 1
Funnel plots using response rates as an outcome for a, b thymoma and c–f thymic carcinoma in each chemotherapy category (anthracycline-based vs. non-anthracycline-based and cisplatin-based vs. carboplatin-based)

References

    1. Agatsuma T, Koizumi T, Kanda S, Ito M, Urushihata K, Yamamoto H, Hanaoka M, Kubo K. Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma. J Thorac Oncol. 2011;6(12):2130–2134. doi: 10.1097/JTO.0b013e31822e71c0.
    1. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983;1(11):710–719.
    1. Bernatz PE, Harrison EG, Clagett OT. Thymoma: a clinicopathologic study. J Thorac Cardiovasc Surg. 1961;42:424–444.
    1. Berruti A, Borasio P, Gerbino A, Gorzegno G, Moschini T, Tampellini M, Ardissone F, Brizzi MP, Dolcetti A, Dogliotti L. Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience. Br J Cancer. 1999;81(5):841–845. doi: 10.1038/sj.bjc.6690773.
    1. de Jong WK, Blaauwgeers JL, Schaapveld M, Timens W, Klinkenberg TJ, Groen HJ. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer. 2008;44(1):123–130. doi: 10.1016/j.ejca.2007.11.004.
    1. Detterbeck FC, Asamura H, Crowley J, Falkson C, Giaccone G, Giroux D, Huang J, Kim J, Kondo K, Lucchi M, Marino M, Marom EM, Nicholson A, Okumura M, Ruffini E, van Schil P, Stratton K, Staging, Prognostic Factors C. Members of the Advisory B. Participating Institutions of the Thymic D The IASLC/ITMIG thymic malignancies staging project: development of a stage classification for thymic malignancies. J Thorac Oncol. 2013;8(12):1467–1473. doi: 10.1097/JTO.0000000000000017.
    1. Engel P, Marx A, Muller-Hermelink HK. Thymic tumours in Denmark. A retrospective study of 213 cases from 1970-1993. Pathol Res Pract. 1999;195(8):565–570. doi: 10.1016/S0344-0338(99)80006-5.
    1. Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol. 2010;5(10 Suppl 4):S260–S265. doi: 10.1097/JTO.0b013e3181f1f62d.
    1. Fornasiero A, Daniele O, Ghiotto C, Piazza M, Fiore-Donati L, Calabro F, Rea F, Fiorentino MV. Chemotherapy for invasive thymoma. A 13-year experience. Cancer. 1991;68(1):30–33. doi: 10.1002/1097-0142(19910701)68:1<30::AID-CNCR2820680106>;2-4.
    1. Furugen M, Sekine I, Tsuta K, Horinouchi H, Nokihara H, Yamamoto N, Kubota K, Tamura T. Combination chemotherapy with carboplatin and paclitaxel for advanced thymic cancer. Jpn J Clin Oncol. 2011;41(8):1013–1016. doi: 10.1093/jjco/hyr089.
    1. Gao L, Wang C, Fang W, Zhang J, Lv C, Fu S. Outcome of multimodality treatment for 188 cases of type b3 thymoma. J Thorac Oncol. 2013;8(10):1329–1334. doi: 10.1097/JTO.0b013e31829ceb50.
    1. Giaccone G, Ardizzoni A, Kirkpatrick A, Clerico M, Sahmoud T, van Zandwijk N. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 1996;14(3):814–820.
    1. Girard N, Lal R, Wakelee H, Riely GJ, Loehrer PJ. Chemotherapy definitions and policies for thymic malignancies. J Thorac Oncol. 2011;6(7 Suppl 3):S1749–S1755. doi: 10.1097/JTO.0b013e31821ea5f7.
    1. Grassin F, Paleiron N, Andre M, Caliandro R, Bretel JJ, Terrier P, Margery J, Le Chevalier T, Ruffie P. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experience. J Thorac Oncol. 2011;5(6):893–897. doi: 10.1097/JTO.0b013e3181db3dee.
    1. Huang J, Detterbeck FC, Wang Z, Loehrer PJ., Sr Standard outcome measures for thymic malignancies. J Thorac Oncol. 2010;5(12):2017–2023. doi: 10.1097/JTO.0b013e3181f13682.
    1. Igawa S, Murakami H, Takahashi T, Nakamura Y, Tsuya A, Naito T, Kaira K, Ono A, Shukuya T, Tamiya A, Endo M, Yamamoto N. Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma. Lung Cancer. 2010;67(2):194–197. doi: 10.1016/j.lungcan.2009.03.031.
    1. Kawashima Y, Inoue A, Sugawara S, Harada M, Kobayashi K, Kozuki T, Kuyama S, Sakakibara T, Maemondo M, Asahina H, Hisamoto A, Nakagawa T, Nukiwa T (2013) Phase II study of amrubicin (AMR) and carboplatin (CBDCA) for invasive thymoma (IT) and thymic carcinoma (TC): NJLCG0803. ASCO Meeting Abstracts 31(15_suppl):7530
    1. Kim ES, Putnam JB, Komaki R, Walsh GL, Ro JY, Shin HJ, Truong M, Moon H, Swisher SG, Fossella FV, Khuri FR, Hong WK, Shin DM. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer. 2004;44(3):369–379. doi: 10.1016/j.lungcan.2003.12.010.
    1. Kunitoh H, Tamura T, Shibata T, Nakagawa K, Takeda K, Nishiwaki Y, Osaki Y, Noda K, Yokoyama A, Saijo N, Jcog Lung Cancer Study Group TJ A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605) Br J Cancer. 2009;101(9):1549–1554. doi: 10.1038/sj.bjc.6605347.
    1. Lauriola L, Erlandson RA, Rosai J. Neuroendocrine differentiation is a common feature of thymic carcinoma. Am J Surg Pathol. 1998;22(9):1059–1066. doi: 10.1097/00000478-199809000-00003.
    1. Lemma GL, Lee JW, Aisner SC, Langer CJ, Tester WJ, Johnson DH, Loehrer PJ., Sr Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol. 2011;29(15):2060–2065. doi: 10.1200/JCO.2010.32.9607.
    1. Levine GD, Rosai J. Thymic hyperplasia and neoplasia: a review of current concepts. Hum Pathol. 1978;9(5):495–515. doi: 10.1016/S0046-8177(78)80131-2.
    1. Loehrer PJ Sr, Kim K, Aisner SC, Livingston R, Einhorn LH, Johnson D, Blum R (1994) Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 12(6):1164–1168
    1. Loehrer PJ, Sr, Chen M, Kim K, Aisner SC, Einhorn LH, Livingston R, Johnson D. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol. 1997;15(9):3093–3099.
    1. Loehrer PJ, Sr, Jiroutek M, Aisner S, Aisner J, Green M, Thomas CR, Jr, Livingston R, Johnson DH. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer. 2001;91(11):2010–2015. doi: 10.1002/1097-0142(20010601)91:11<2010::AID-CNCR1226>;2-2.
    1. Lucchi M, Melfi F, Dini P, Basolo F, Viti A, Givigliano F, Angeletti CA, Mussi A. Neoadjuvant chemotherapy for stage III and IVA thymomas: a single-institution experience with a long follow-up. J Thorac Oncol. 2006;1(4):308–313. doi: 10.1097/01243894-200605000-00007.
    1. Masaoka A. Staging system of thymoma. J Thorac Oncol. 2010;5(10 Suppl 4):S304–S312. doi: 10.1097/JTO.0b013e3181f20c05.
    1. Monica V, Familiari U, Chiusa L, Rossi G, Novero D, Busso S, Ruffini E, Ardissone F, Scagliotti GV, Papotti M. Messenger RNA and protein expression of thymidylate synthase and DNA repair genes in thymic tumors. Lung Cancer. 2013;79(3):228–235. doi: 10.1016/j.lungcan.2012.12.003.
    1. Muller-Hermelink HK, Marino M, Palestro G. Pathology of thymic epithelial tumors. Curr Top Pathol. 1986;75:207–268. doi: 10.1007/978-3-642-82480-7_7.
    1. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346(2):85–91. doi: 10.1056/NEJMoa003034.
    1. Noguchi T, Hanada M, Yamaoka T (2005) Development of a novel anti-tumor drug ‘amrubicin’, a completely synthetic anthracycline. SUMITOMO KAGAKU 2005-II:1–11
    1. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol. 2007;18(2):317–323. doi: 10.1093/annonc/mdl377.
    1. Okuma Y, Hosomi Y, Takagi Y, Iguchi M, Okamura T, Shibuya M. Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity. Lung Cancer. 2011;74(3):492–496. doi: 10.1016/j.lungcan.2011.05.013.
    1. Park S, Ahn MJ, Ahn JS, Sun JM, Shim YM, Kim J, Choi YS, Kim K, Shin S, Ahn Y, Kwon OJ, Kim H, Lee SJ, Chang WJ, Park K. A prospective phase II trial of induction chemotherapy with docetaxel/cisplatin for Masaoka stage III/IV thymic epithelial tumors. J Thorac Oncol. 2013;8(7):959–966. doi: 10.1097/JTO.0b013e318292c41e.
    1. Rea F, Sartori F, Loy M, Calabro F, Fornasiero A, Daniele O, Altavilla G. Chemotherapy and operation for invasive thymoma. J Thorac Cardiovasc Surg. 1993;106(3):543–549.
    1. Rosai J (1999) Histological typing of tumours of the thymus. In: World Health Organization International Histological Classification of Tumours. Springer, Berlin
    1. Schmitt J, Loehrer PJ., Sr The role of chemotherapy in advanced thymoma. J Thorac Oncol. 2010;5(10 Suppl 4):S357–S360. doi: 10.1097/JTO.0b013e3181f21129.
    1. Sugiura H, Fujiwara Y, Ando M, Kawai A, Ogose A, Ozaki T, Yokoyama R, Hiruma T, Ishii T, Morioka H, Mugishima H. Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma. J Orthop Sci. 2010;15(5):654–660. doi: 10.1007/s00776-010-1506-9.
    1. Takeda K, Hirai F, Yamanaka T, Taguchi K, Daga H, Shimizu J, Kogure Y, Kimura T, Tanaka K, Iwamoto Y, Ono A, Sasaki H, Fukuoka J, Nishiyama K, Seto T, Ichinose Y, Nakagawa K, Nakanishi Y, West Japan Oncology Group (2013) A multicenter prospective study of carboplatin and paclitaxel for advanced thymic carcinoma: West Japan Oncology Group 4207L. ASCO Meeting Abstracts 31(15_suppl):7529
    1. Travis W, Brambilla W, Müller-Hermelink H, Harris C (2004) World Health Organization classification of tumors. Pathology and genetics of tumors of the lung, pleura, thymus and heart. Chapter 3. IARC press, Lyon
    1. Weksler B, Dhupar R, Parikh V, Nason KS, Pennathur A, Ferson PF. Thymic carcinoma: a multivariate analysis of factors predictive of survival in 290 patients. Ann Thorac Surg. 2013;95(1):299–303. doi: 10.1016/j.athoracsur.2012.09.006.
    1. Yoh K, Goto K, Ishii G, Niho S, Ohmatsu H, Kubota K, Kakinuma R, Nagai K, Suga M, Nishiwaki Y. Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma. Cancer. 2003;98(5):926–931. doi: 10.1002/cncr.11606.
    1. Yokoi K, Matsuguma H, Nakahara R, Kondo T, Kamiyama Y, Mori K, Miyazawa N. Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone. J Thorac Oncol. 2007;2(1):73–78. doi: 10.1097/JTO.0b013e31802bafc8.
    1. Zucali PA, Di Tommaso L, Petrini I, Battista S, Lee HS, Merino M, Lorenzi E, Voulaz E, De Vincenzo F, Simonelli M, Roncalli M, Giordano L, Alloisio M, Santoro A, Giaccone G. Reproducibility of the WHO classification of thymomas: practical implications. Lung Cancer. 2013;79(3):236–241. doi: 10.1016/j.lungcan.2012.11.015.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera